Journal of International Research in Medical and Pharmaceutical Sciences

Pharmaceutical manufacturing occupies an unusual position in the sustainability debate. It produces goods of exceptional social value through processes that are among the most material-intensive in the chemical sector, and it does so under regulatory constraints that penalise process change. Three research programmes have developed in response: the redesign of synthetic chemistry around catalysis and benign solvents, the application of computational and data-driven methods to route and process design, and the reorganisation of production around material recovery and reuse. These programmes are usually reviewed separately, which obscures the extent to which they depend upon, and occasionally undermine, one another. This critical narrative review examines the small-molecule and synthetic-peptide manufacturing literature published between 1998 and June 2026, with emphasis on evidence generated at pilot or manufacturing scale rather than at laboratory scale alone. Literature was identified through structured bibliographic searching of a metadata registry, targeted scholarly web searching and the publications of intergovernmental and regulatory bodies, and was appraised for design adequacy, scale of demonstration, independence of confirmation and transparency of reporting. The evidence is strongest for biocatalytic substitution of stoichiometric and precious-metal chemistry, where independent manufacturing-scale demonstrations and consistent mass-efficiency gains converge. It is moderate for solvent substitution and continuous processing, where selection guides and case studies are abundant but comparative and independently audited data remain scarce. It is weak, though not negative, for photochemical, electrochemical and mechanochemical activation at manufacturing scale, and for digital methods, whose reported gains derive predominantly from retrospective or single-laboratory studies. Circularity remains largely confined to solvent recovery; broader material loops are asserted more often than measured. Mass-based metrics, principally process mass intensity, have driven substantial improvement but conceal energy, toxicity and upstream burdens, and they compare poorly across therapeutic modalities. Progress now depends less on new chemistry than on comparable measurement, independent verification and regulatory pathways that permit process improvement after approval.